A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)
Information source: Novartis
Information obtained from ClinicalTrials.gov on October 19, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: SPP100 (Drug)
Phase: Phase 2
Sponsored by: Novartis
Official(s) and/or principal investigator(s):
Novartis Pharmaceuticals, Study Director, Affiliation: Novartis
This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)
Long-Term Treatment, Multicenter, Open-Label Study With SPP100 in Patients With Essential Hypertension
Study design: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Incidence of adverse events, vital signs, abnormal laboratory changes,etc.
Change from baseline in diastolic blood pressure after 52 weeks
Change from baseline in systolic blood pressure after 52 weeks
Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 52 weeks
Minimum age: 20 Years.
Maximum age: 80 Years.
- Diagnosed as essential hypertension -
- Patients with secondary hypertension or suspected of having secondary hypertension.
- Patients suspected of having malignant hypertension
- Patients with any serious diseases or symptoms
Locations and Contacts
Novartis Pharmaceuticals, Basel, Switzerland
Last updated: July 27, 2006